Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Forthright who wrote (749)	5/17/1998 7:22:00 PM
From: F. Jay Abella, III	Read Replies (1) \| Respond to of 1185

Mr. Forthright: W/r/t to your points - You are correct about biotech deals; in fact if you look at CEGE, they have a deal for AIDS with Roche valued at 160mm total. I think the deal was signed in 1995, from which CEGE has yet to receive the bulk of the money, as they have not reached a majority of the milestones to date. It takes years. Negotiating the FDA/HPB regulatory process is about the most difficult of human pursuits. One slip up in ten years and you can't go back. That's why Roche is a good partner for NRT; the junior biotech will benefit greatly from the experience and may have solidified long term value if milestones are met. Keep in mind, the NPV of 10% of NRT's technology was $86.5mm US. Not bad. w/r/t our conferences, NRT came to our biomed conference last June and paid a fee. I hope they come back this year but have not confirmed. You should note that just because a company cohosts a conference, does not preclude a favorable report from me. For example, when was the last time I commented positively, if at all, on AVII? They were also a conference company. I call 'em the way I see 'em. And since my relationship with NRT began, the stock is about 3 times what it was this year last time, even after the recent decline. You are right in thinking its still early, but IMO, these guys will do very well long term. Investors like SOROS, if they have patience and guts long term, stand to make a bloody fortune behind the brilliance of NRT scientists. I for one hope he makes it. FJA PS - As far as the best analysts in Canada, I don't know. But how many of them were negative on IZP in the mid 2's, bullish on NRT well below a buck, and IDBEF at 2.75US? In fact forthright would be interested to know that IZP came to our Nov 96 conference and misled our audience about its oral asthma drug. The relationship terminated right there. I understand IZP is under new management, so we'll see if Apanol is a good drug at some point. w/r/t IDBEF, they have never showed us any interest in ever working with us. However, after I performed a valuation on them, I saw the company as having some room on the upside. Amazingly, the stock is now quite close to my valuation number. I wish that IDBEF would pursue a relationship with us. However, my call about their stock and its value may say something about my analytical (versus promotional skills). I always view this as a positive.